Drugs / Adenorine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06509880 | Jul 2022 → Jul 2023 | — | MIPO Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenorine | “Sodium nucleinate (Adenorine) is an immunomodulatory oligonucleotide preparation.” NCT06509880 ↗ |
| Modality | Oligonucleotide (other) | “Sodium nucleinate (Adenorine) is an immunomodulatory oligonucleotide preparation.” NCT06509880 ↗ |
| Route | Oral | “it was administered orally at 50 mg per day” NCT06509880 ↗ |